Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPL as Adjunctive to Brimonidine for Rosacea
NCT03053700Phase 4Withdrawn
- Sponsor
- Rabin Medical Center
- Start
- Dec 2018
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (2 arms), sponsored by Rabin Medical Center. Primary endpoints: Patient self-assessment questionnaire score change at 6 months and Physicians' unblinded score assessment at 6 months. Planned start Dec 2018; status: withdrawn.
Beyond the preview
Go deeper on NCT03053700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053700.